ArticleNature2024
Commensal consortia decolonize Enterobacteriaceae via ecological control.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A human gut metagenome-assembled genome catalogue spanning 41 countries supports genome-scale metabolic models.Nature microbiology · 2026Pooled it
- Translational efficiency guides microbial community remodeling.Gut microbes · 2026Article
- Review
- Klebsiella genus as driver of human disease: from infections to non-communicable disorders.Nature reviews. Microbiology · 2026Review
- Microbiome ecology and antibiotic treatment failure: resistance spread, microbial competition and community engineering.Microbial genomics · 2026Review
- Antisense transcription reveals disease-associated adaptations in the human gut microbiome.Nature microbiology · 2026Article
- Metabolic strategies of Enterobacteriaceae gut colonization.Nature reviews. Microbiology · 2026Review
- Next-generation probiotics: an outlook into current applications and future developments.Nature reviews. Microbiology · 2026Review
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Profiling the gut resistome to unlock antimicrobial resistance biology and inform clinical risk.Nature communications · 2026Review
- Molecular Mechanisms of Gut Microbiota-Immune System Crosstalk: From Mucosal Architecture to Adaptive Immunity Programming.International journal of molecular sciences · 2026Review
- Prodrug-integrated multifunctional liposome encapsulation enhances probiotic-based bacteriotherapy for inflammatory bowel disease.Materials today. Bio · 2026Article
- Harnessing the microbiome for cancer therapy.Nature reviews. Microbiology · 2026Review
- Characteristics of gut microbiota changes in patients with nasopharyngeal carcinoma during radiotherapy.Journal of translational medicine · 2026Article
- Probiotics in colorectal cancer: mechanisms, biomarkers, and adjunct strategies.Cancer biology & medicine · 2026Review
- Enhancements of symbiotic adhesion and antibiotic efficacy observed by the metabolic crosstalk within cell-bacteria cocultured on a microfluidic gut chip.Journal of pharmaceutical analysis · 2026Article
- Environmental redox conditions and strain variation define phenazine-mediated antagonism in co-infecting bacteria.PLoS biology · 2026Article
- Ketogenic diet exacerbates DSS-induced colitis through a β-hydroxybutyrate-Thomasclavelia spiroformis-γδ17 T cell axis in mice.Nature communications · 2026Article
- Metabiosis underlies a microbiota permissive to Pseudomonadota and increases the risk of gut-borne bloodstream infection.bioRxiv : the preprint server for biology · 2026Article
- The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome.Chinese medicine · 2026Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
34 authors.
Munehiro Furuichi *Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-7742-1135
Takaaki Kawaguchi *Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-3354-961X
Marie-Madlen Pust *Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Keiko Yasuma-Mitobe *Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-7102-987X
Damian R PlichtaInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-6555-2557
Naomi HasegawaDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Takashi OhyaDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Shakti K BhattaraiDepartment of Microbiology and Physiological Systems, Program in Microbiome Dynamics, UMass Chan Medical School, Worcester, MA, USA.
Satoshi SasajimaDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Yoshimasa AotoJSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan.
Timur TuganbaevDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Mizuki YaginumaDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Masahiro UedaRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-8814-7071
Nobuyuki OkahashiRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-9582-355X
Kimiko AmafujiJSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan.
Yuko KiridoshiJSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan.
Kayoko SugitaDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Martin StražarInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-3064-1055
Julian Avila-PachecoInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9388-3946
Kerry PierceInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Clary B ClishInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8259-9245
Ashwin N SkellyDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-1565-3376
Masahira HattoriRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Nobuhiro NakamotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-5203-7444
Silvia CaballeroVedanta Biosciences, Cambridge, MA, USA.
Jason M NormanVedanta Biosciences, Cambridge, MA, USA.ORCID 0000-0001-5049-8415
Bernat OlleVedanta Biosciences, Cambridge, MA, USA.
Takeshi TanoueDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0003-3639-8834
Wataru SudaRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Makoto AritaRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-9902-0463
Vanni BucciDepartment of Microbiology and Physiological Systems, Program in Microbiome Dynamics, UMass Chan Medical School, Worcester, MA, USA.ORCID 0000-0002-3257-2922
Koji AtarashiDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-5422-0736
Ramnik J XavierInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. xavier@molbio.mgh.harvard.edu.ORCID 0000-0002-5630-5167
Kenya HondaDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. kenya@keio.jp.ORCID 0000-0001-8937-9835
Funding
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3MDeterminants of inception of inflammation in inflammatory bowel diseasesR01DK127171 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANANTHAKRISHNAN, ASHWIN N, XAVIER, RAMNIK J · 2021 to 2025
$5.4MIdentification and Characterization of Microbial Metabolites in ImmunityR01AI172147 · NIAID · BROAD INSTITUTE, INC. · PI Daniel Bartholomew Graham, Ramnik J Xavier · 2022 to 2026
$3.9MCardiovascular disease, metabolic syndrome, microbes and metabolites in FHSR01HL157717 · NHLBI · BROAD INSTITUTE, INC. · PI XAVIER, RAMNIK J · 2022 to 2025
$3.9MNHLBI NIH HHS R01 HL157717NIAID NIH HHS R01 AI172147NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK127171
Abstract
Persistent colonization and outgrowth of potentially pathogenic organisms in the intestine can result from long-term antibiotic use or inflammatory conditions, and may perpetuate dysregulated immunity and tissue damage
Indexed as
EnterobacteriaceaeEnterobacteriaceae InfectionsGastrointestinal MicrobiomeSymbiosisAnimalsDrug Resistance, BacterialEscherichiaFecesGluconatesHumansInflammationIntestinesKlebsiellaMiceMice, Inbred C57BLProbioticsGluconatesgluconic acid
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.